Foghorn Therapeutics Inc FHTX

$2.07 +0.02 (0.98%)

Valuation

Market cap
124,123,000
Revenue TTM
$30,910,000
Net income TTM
$-74,280,000
P/E (trailing)
29.29
P/E (forward)
—
Profit margin
-240.31%
Debt to equity
0.00

Trading

Volume
534,200
Avg volume
915,282
Day's range
$1.94 – $2.08
Shares out
59,963,000
Stochastic %K
57%
Beta
3.22
Analysts
Moderate Buy
Price target
$5.00

Price

Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell...

Show more

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 586 3100
Website
https://foghorntx.com
Address
99 Coolidge Avenue, Suite 500, Watertown, United States

Latest news

No headlines yet.